
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech Inc has demonstrated a positive trajectory in its clinical developments, notably through favorable data emerging from its Phase 2 studies involving Ampligen, which hold significant potential for treating post-COVID conditions and colorectal cancer. The consistent trend of positive trial results could serve as strong catalysts for future stock performance, reflecting the company's promising position in the immuno-pharmaceutical sector. With its focus on addressing unmet medical needs in various diseases, AIM ImmunoTech's robust pipeline underlines its strategic importance and potential for growth.
Bears say
AIM ImmunoTech Inc reported a net loss of $3.3 million, translating to an earnings per share (EPS) of $(1.57), which exceeded both internal and consensus estimates, indicating greater-than-anticipated operational challenges. Additionally, the company continues to face significant risks, including balance sheet and liquidity concerns, unsuccessful clinical trials, and hurdles in gaining regulatory approvals, which collectively heighten uncertainty regarding its future profitability and market position. The combination of these financial losses and operational risks contributes to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares